Vortioxetine has the potential to be an effective drug in MDD-SUD because it is the antidepressant with the greatest efficacy on cognitive dysfunction associated with MDD owing to 5-HT3 and 5-HT7 receptor blockade [101, 135, 141, 148, 152, 257]. Here, HTR3A is linked to major depressive disorder.